December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Sanofi Winthrop Industrie

< Previous 1 2 3 Next >
News headline image
Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press release: Availability of the Q1 2026 aide-mémoire
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release:  Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press release: Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Belén Garijo to become Chief Executive Officer of Sanofi
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi completes the acquisition of Dynavax
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi announces the signing of a share buyback mandate for up to €1 billion
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press release: 2025: strong sales and EPS growth. Continued profitable growth expected in 2026
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Myqorzo and Redemplo approved in China
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia
From Sanofi Winthrop Industrie
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.